Vonoprazan Drug Class
Vonoprazan belongs to the potassium-competitive acid blocker (P-CAB) class of medications. 1, 2
Mechanism of Action
P-CABs represent a distinct class from proton pump inhibitors (PPIs), though both suppress gastric acid secretion. Vonoprazan works through ionic (reversible) binding that blocks access of potassium (K+) to the potassium-binding site of the gastric proton pump, rather than the covalent (irreversible) binding to cysteines that characterizes PPIs. 1
Key Pharmacological Distinctions from PPIs
Vonoprazan differs from PPIs in several critical ways:
- Not a prodrug - Does not require conversion to an active form, enabling more rapid onset of action 1
- Acid-stable - Unlike PPIs which are acid-labile and require enteric coating 1
- Longer half-life - 6-9 hours compared to 1-2 hours for PPIs 1
- Meal-independent dosing - Can be taken without regard to meals, unlike PPIs which require administration 30-60 minutes before meals 1
- Faster onset - Achieves maximal acid suppression within 1 day versus 3-5 days for PPIs 1
- CYP2C19-independent metabolism - Not significantly affected by genetic polymorphisms that impact PPI efficacy 1
FDA Classification
The FDA formally describes vonoprazan fumarate as "a potassium-competitive acid blocker" in its official drug labeling, confirming this as the established drug class designation. 2
P-CABs approved or in development include: revaprazan, vonoprazan, tegoprazan, fexuprazan, linaprazan, zastaprazan, and keverprazan. 1